A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PPA / phenylpropanolamine

[Related PubMed/MEDLINE]
Total Number of Papers: 184
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PPA  (>> Co-occurring Abbreviation)
Long Form:   phenylpropanolamine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Myocardial hypertrophy associated with long-term phenylpropanolamine use in a dog. ---
2017 Mediation of oxidative stress in hypothalamic ghrelin-associated appetite control in rats treated with phenylpropanolamine. AG, CART, GOAT, NPY
2017 Simultaneous determination of cetirizine, phenyl propanolamine and nimesulide using third derivative spectrophotometry and high performance liquid chromatography in pharmaceutical preparations. CET, CTZ, NMS
2016 Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles. FDA, SR
2015 Changes in blood pressure following escalating doses of phenylpropanolamine and a suggested protocol for monitoring. BW
2015 Targeting oxidative stress in the hypothalamus: the effect of transcription factor STAT3 knockdown on endogenous antioxidants-mediated appetite control. JAK2, NPY, POMC, ROS, STAT3
2014 Gonadotropin-releasing hormone immunization for the treatment of urethral sphincter mechanism incompetence in ovariectomized bitches. ---
2013 Inhibiting neuropeptide Y Y1 receptor modulates melanocortin receptor- and NF-kappaB-mediated feeding behavior in phenylpropanolamine-treated rats. MC4R, NF-kappaB, NPY, Y1R
2013 Neuropeptide Y Y1 receptor knockdown can modify glutathione peroxidase and c-AMP response element-binding protein in phenylpropanolamine-treated rats. CREB, GP, NPY, Y1R
10  2013 Systemic hypertension and hypertensive retinopathy following PPA overdose in a dog. AST, CK, OU
11  2013 The identification of neuropeptide Y receptor subtype involved in phenylpropanolamine-induced increase in oxidative stress and appetite suppression. NPY, SOD, Y1R, Y5R
12  2012 Determination of the active principles of Catha Edulis: quali-quantitative analysis of cathinone, cathine, and phenylpropanolamine. ---
13  2012 Knocking down the transcript of NF-kappaB modulates the reciprocal regulation of endogenous antioxidants and feeding behavior in phenylpropanolamine-treated rats. GPx, NPY, SOD
14  2012 Urodynamic and haemodynamic effects of a single oral administration of ephedrine or phenylpropanolamine in continent female dogs. UPP
15  2011 Artificial neural network combined with principal component analysis for resolution of complex pharmaceutical formulations. ANN, CAF, MEP, PCA, PCs, PLS2, PNA, SEP
16  2011 Clinical evaluation of a single daily dose of phenylpropanolamine in the treatment of urethral sphincter mechanism incompetence in the bitch. BW, UPP, USMI
17  2011 Effects of phenylpropanolamine (PPA) on in vitro human erythrocyte membranes and molecular models. DMPC, DMPE, IUM, LUV, SEM
18  2011 Posterior reversible encephalopathy syndrome complicating intracranial hemorrhage after phenylpropanolamine exposure. ICH, PRES
19  2011 Role of reactive oxygen species-related enzymes in neuropeptide y and proopiomelanocortin-mediated appetite control: a study using atypical protein kinase C knockdown. aPKC, NPY, POMC, ROS-RE
20  2011 Spectrophotometric determination of certain CNS stimulants in dosage forms and spiked human urine via derivatization with 2,4-Dinitrofluorobenzene. DNFB, EPH, LOD, LOQ, PSE
21  2010 A New Spectrophotometric Method for Determination of Phenylpropanolamine HCl in its Pharmaceutical Formulations via Reaction with 2,3,5,6-tetrachloro-1,4-benzoquinone. LOD, LOQ
22  2010 Combined pharmacokinetic and urodynamic study of the effects of oral administration of phenylpropanolamine in female Beagle dogs. USMI
23  2010 The effect of protein kinase C-delta knockdown on anti-free radical enzyme and neuropeptide Y gene expression in phenylpropanolamine-treated rats. CAT, NOS, NPY, PKC
24  2009 Boltushka: a homemade amphetamine-type stimulant and HIV risk in Odessa, Ukraine. ATSs, IDUs, RPAR
25  2009 Influences of urinary pH on the pharmacokinetics of three amphetamine-type stimulants using a new high-performance liquid chromatographic method. ASC, ATS, AUC, FEN, HPLC, MRT, PSE
26  2009 Interventions for preventing weight gain after smoking cessation. CBT, RR
27  2009 Roles of protein kinase Calpha isozyme in the regulation of oxidative stress and neuropeptide Y gene expression in phenylpropanolamine-mediated appetite suppression. NPY, PKC, POMC, SOD
28  2008 Are non-prescription medications needed for weight control? FDA, OTC
29  2008 Interrupting activator protein-1 signaling in conscious rats can modify neuropeptide Y gene expression and feeding behavior of phenylpropanolamine. AP-1, NPY, SOD
30  2008 Protracted 'anti-addictive' effects of adolescent phenylpropanolamine exposure in C57BL/6J mice. NAc, OTC
31  2008 Transcriptional interruption of cAMP response element binding protein modulates superoxide dismutase and neuropeptide Y-mediated feeding behavior in freely moving rats. CREB, NPY, SOD-2
32  2007 Effect of phenylpropanolamine and pseudoephedrine on the urethral pressure profile and continence scores of incontinent female dogs. PD
33  2007 Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. HS
34  2007 Protracted 'pro-addictive' phenotype produced in mice by pre-adolescent phenylpropanolamine. OTC
35  2007 Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression. CAT, NPY
36  2007 Transcript of protein kinase A knock-down modulates feeding behavior and neuropeptide Y gene expression in phenylpropanolamine-treated rats. CREB, NPY, PKA, POMC
37  2007 [Efficacy, tolerance and acceptability of Incontex in spayed bitches with urinary incontinence]. ---
38  2006 Capillary gas chromatographic determination of phenylpropanolamine in pharmaceutical preparation. RSD
39  2006 Metabolites of ephedrines in human urine after administration of a single therapeutic dose. EPH, GC-MS, MEPH, OTC, PEPH, TBME, TFAA
40  2006 Phenylpropanolamine and hemorrhagic stroke in the Hemorrhagic Stroke Project: a reappraisal in the context of science, the Food and Drug Administration, and the law. FDA, HSP
41  2005 A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. ---
42  2005 Reparation of controlled release spheronized beads by simple extrusion and modified spheronization process. ---
43  2005 Simultaneous determination of loratadine and pseudoephedrine sulfate in human plasma by liquid chromatography-electrospray mass spectrometry for pharmacokinetic studies. DP, LC-MS, LOR, PES
44  2004 Antioxidant-independent ascorbate enhancement of catecholamine-induced contractions of vascular smooth muscle. EPH, NE
45  2004 Cerebral infarcts in a pediatric patient secondary to phenylpropanolamine, a recalled medication. FDA
46  2004 Evaluation of ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine samples and a comparison of the specificity of DRI amphetamines and Abuscreen online (KIMS) amphetamines screening immunoassays. AMP, EPH, GC/MS, MDA, MDMA, MTH, PSEPH
47  2004 High performance liquid chromatography with fluorescence detection for the determination of phenylpropanolamine in human plasma and rat's blood and brain microdialysates using DIB-Cl as a label. DIB-Cl, EP, FL
48  2004 Immunohistochemical and genomic evidence for the involvement of hypothalamic neuropeptide Y (NPY) in phenylpropranolamine-mediated appetite suppression. NPY
49  2004 Pharmacokinetic interactions between phenylpropanolamine, caffeine and chlorpheniramine in rats. ---
50  2004 Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. IUP, MAP
51  2003 Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice. DA
52  2003 Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction. ---
53  2003 Ephedrines in over-the-counter cold medicines and urine specimens collected during sport competitions. EPH, GC-NPD, IOC, MEPH, MS, OTC, PEPH
54  2003 Pharmacological characterization of the novel histamine H3-receptor antagonist N-(3,5-dichlorophenyl)-N'-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH 79687). BP, EFS, GP, HSV
55  2003 Phenylpropanolamine and intracranial hemorrhage risk in a Mexican population. ICH, SAH
56  2003 Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. ---
57  2003 The effect of GnRH analogs on urinary incontinence after ablation of the ovaries in dogs. ---
58  2002 Effects of selegiline, phenylpropanolamine, or a combination of both on physiologic and behavioral variables in healthy dogs. ---
59  2002 HPLC determination of phenylpropanolamine in pharmaceutical OTC preparations. CPA, OTC, PE
60  2002 Phenylpropanolamine appears not to promote weight loss in patients with schizophrenia who have gained weight during clozapine treatment. PANSS
61  2002 Regulatory decisions in a globalised world: the domino effect of phenylpropanolamine withdrawal in Latin America. FDA
62  2001 HPLC determination of phenylpropanolamine in pharmaceutical preparations using 4-dimethylaminobenzaldehyde as a derivatizing reagent. DAB, HPLC
63  2001 Influence of a combination of herbs on appetite suppression and weight loss in rats. ---
64  2001 MCC resolves on phenylpropanolamine (PPA) safety. ---
65  2001 Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. ---
66  2001 Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. ---
67  2001 Tyrosine improves behavioral and neurochemical deficits caused by cold exposure. AMPH, NE, SAL, Tyr
68  2000 Inhibition of nitric oxide synthase enhances the myocardial toxicity of phenylpropanolamine. L-NAME
69  1999 Changes in nasal resistance and nasal geometry using pressure and acoustic rhinometry in a feline model of nasal congestion. AcR, NAR
70  1999 Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion. AcR, CLOB, NAR, RAN, THIO
71  1999 Double-blind, randomized, placebo-controlled clinical trials with non-prescription medications for the treatment of obesity. ---
72  1999 Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects. ---
73  1999 Validation of cough-induced leak point pressure measurement in the evaluation of pharmacological treatment of stress incontinence. CILPP, MUP
74  1998 Intracerebral hemorrhage in a young woman with arteriovenous malformation after taking diet control pills containing phenylpropanolamine: a case report. ---
75  1997 Acute administration of phenylpropanolamine fails to affect resting energy expenditure in men of normal weight. REE, RQ
76  1997 Assessment of the role of oxytocin receptors in phenylpropanolamine-induced anorexia in rats. PVN
77  1997 Do pseudoephedrine or phenylpropanolamine improve maximum oxygen uptake and time to exhaustion? BPs, PSE
78  1997 Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats. ---
79  1997 Hair analysis for drugs of abuse. XIX. Determination of ephedrine and its homologs in rat hair and human hair. EP, MA, ME, PFPA, TFAA
80  1996 Effects of systemic phenylpropanolamine and fenfluramine on serotonin activity within rat paraventricular hypothalamus. FEN, PFH, PVN
81  1995 An experimental model for long-term examinations of urethral and uterine pressures in conscious dogs: effect of a highly selective compound contracting urethral smooth muscles. ---
82  1995 Cerebral arteritis associated with oral use of phenylpropanolamine: report of a case. ---
83  1995 Effects of phenylpropanolamine on withdrawal symptoms. ---
84  1995 Isobolographic assessment of the effects of combinations of phenylpropanolamine and fenfluramine on food intake in rats. FEN, PVN
85  1995 [Comparison of multiple dosage bioavailability between phenylpropanolamine controlled release suspension and conventional tablet in healthy volunteers]. CRS, FI
86  1994 Conditioned taste aversion in rats induced by the alpha 1-adrenoceptor agonist cirazoline. CTA, PVN
87  1994 Phenylpropanolamine-induced psychosis. Potential predisposing factors. ---
88  1993 An assessment of the involvement of paraventricular hypothalamic alpha 2-adrenoceptors in phenylpropanolamine anorexia. NE, PVN
89  1993 Comparison between phenylpropanolamine and structurally related compounds on gastric transit in the rat. ---
90  1993 Effect of phenylpropanolamine and related compounds on beta-adrenoceptor-induced activation of adenylyl cyclase. cAMP, EPI, NE
91  1993 Effect of phenylpropanolamine on energy expenditure and weight loss in overweight women. BMR, EE, OROS, RQ
92  1993 Effects of intra-PVN injections of d- and l-norephedrine on feeding in rats. NEP, PVN
93  1993 Effects of phenylpropanolamine infusion and withdrawal on body weight and dietary composition in male and female rats. ---
94  1993 Effects on food and water intake of the alpha 1-adrenoceptor agonists amidephrine and SK&F-89748. PVN
95  1993 Lack of involvement of 4-hydroxynorephedrine in phenylpropanolamine-induced anorexia in rats. ---
96  1993 National Association of Medical Examiners Pediatric Toxicology Registry. Report 2: Phenylpropanolamine update. NAME, PedTox
97  1993 The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations. AMPHET, CAF, COC, EPHED, OTC, SAL
98  1992 Clinical studies with phenylpropanolamine: a metaanalysis. ---
99  1992 Comparative brain levels of phenylpropanolamine and amphetamine in rats. ---
100  1992 Cytotoxic and morphological effects of phenylpropanolamine, caffeine, nicotine, and some of their metabolites studied In vitro. ENDO